Kazia Therapeutics reports preliminary results from Phase 1b trial

Kazia Therapeutics (KZIA) announces preliminary results from the first patient in its Phase 1b trial evaluating a combination regimen of Paxalisib, pembrolizumab, and standard chemotherapy after completing Cycle 1 of dosing. The patient, a 61-year-old woman with metastatic triple-negative breast cancer localized to the left upper lobe of the lung, has shown highly encouraging preliminary results at 21 days, with a greater than 50% reduction in circulating tumor cells and a notable decrease in CTC clusters. Results at Day 21: 50% reduction in total CTC count. Comparable reduction in CTC clusters-these aggregates are associated with heightened metastatic potential. Reduction in the mesenchymal phenotype of the remaining CTCs; this phenotype is one of the hallmarks of aggressive metastatic seeding cancer cells. First-in-human data support potential for potent CTC mobilization suppression by this combination.